Steele, Shelby
Revolution Medicines (United States)
2 papers on CoChatORCID 0000-0001-8816-4752
Most cited papers
- Verified
Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Jiang, L., Menard, M., Weller, C., Wang, Z., Burnett, L., Aronchik, I., Steele, S., Flagella, M., Zhao, R., Evans, J. W. W., et al. (2023) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 76
- Verified
Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models
Knox, J. E., Jiang, J., Burnett, G. L., Liu, Y., Weller, C. E., Wang, Z., McDowell, L., Steele, S. L., Chin, S., Chou, K. J., et al. (2022) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free